EP 2: How Songbird Targets Chronic Inflammation | Radioactive

Scientific concepts, discoveries, and natural/biological phenomena

Inflammation (immune-mediated)

• Inflammation is described as a response driven by activation of the immune system, leading to the release of factors into the blood and the recruitment/activation of cells that kill pathogens (viruses, bacteria).
• The talk distinguishes:
  • Acute, protective inflammation
  • Chronic inflammation, defined as a low-level persistent inflammatory state that develops over the lifespan and contributes to disease.
• Chronic inflammation is linked to:
  • Metabolic diseases (e.g., obesity, diabetes)
  • Cardiovascular diseases
  • Neurological diseases (e.g., dementia)
  • A reported estimate (as stated in the subtitles): ~60% of deaths linked to chronic inflammation
• Chronic inflammation is also tied to:
  • Health span (years lived in good health)
  • The idea that controlling it could extend health span.

Small intestine as an immune organ (“small intestinal immune axis”)

• The small intestine is framed as:
  • The largest part of the gut by surface area
  • The largest immune organ (as described).
• The proposed mechanism centers on:
  • Dendritic cells in the small intestinal lining sampling the gut lumen content.
  • Dendritic cells extending “tentacle-like” protrusions through tight cell–cell junctions into the lumen.
  • Capturing lumen contents, including:
    • Bacteria
    • Potentially food fragments (proteins/peptides/amino acids are mentioned)
  • After processing, dendritic cells traffic to mesenteric lymph nodes.
  • In lymph nodes, sampled antigens are presented to T cells, helping “educate” the immune system.

Regulatory T cells (Tregs) and immune tolerance

• In lymph nodes, immune activation includes regulatory T cells (Tregs).
• Tregs can be activated depending on which bacteria were encountered in the small intestine.
• Key claim: Tregs drive the immune system toward a balanced/homeostatic (tolerized) state, preventing chronic inflammatory damage.
• The subtitles mention a Nobel Prize awarded “last year” for discovery/understanding of regulatory T cells and their function.

Prevotella histicola as an immunomodulatory trigger

• A central product-related discovery is that Prevotella histicola can:
  • Activate the small intestinal immune axis
  • Trigger/activate regulatory T cells
  • Promote resolution of chronic inflammation
• The approach emphasizes that the immune effect comes from immune recognition of specific structures on the bacterial surface, rather than from the bacteria producing compounds.

Transition from inflammatory biology to a designed intervention

• Referenced studies include:
  • Preclinical studies across multiple inflammatory disease models (described below)
  • Clinical studies (described below)
• The product is described as targeting the immune system through immunological mechanisms, rather than suppressing it directly.

---

Disease models and study types mentioned

Preclinical (animal/model) studies

• Models mentioned:
  • Rheumatoid arthritis
  • Multiple sclerosis
  • Inflammatory bowel disease
• Result claim: administering high doses of Prevotella histicola to the gut leads to resolution of inflammation across these models.

Clinical studies

Psoriasis

• A 225-person clinical study in patients with mild and moderate psoriasis
• Reported design: double-blind, placebo-controlled pharmaceutical study
• Outcome claim:
  • Statistically significant improvement
  • Complete resolution of psoriatic lesions in a significant fraction
• Additional claim:
  • Psoriasis is treated as a systemic inflammatory disease
  • Effects were evaluated using immune biomarkers indicating systemic immune modulation.

COVID-19 (pre-vaccine period)

• A UK government-sponsored study during COVID (before vaccines)
• The study was stopped when vaccines were rolled out
• Data claim: “intriguing” benefit signals in a few hundred patients, framed as helping with the hyperinflammatory immune response.

---

Intervention/product methodology (as outlined)

Product type

• Described as an “immunobiotic” (not simply a probiotic).
• Presented as a supplement-like capsule, not a conventional therapeutic drug.

Bacterial viability

• Delivered Prevotella histicola is described as non-live (non-viable).
• Immune activation is attributed to recognition of structures on bacterial surfaces, not to metabolites or activity produced by live bacteria.

Delivery strategy

• Capsule contains hundreds of billions of cells of the microbe (as stated).
• Uses a stomach-protected formulation to prevent degradation by stomach acid.
• Designed to release quickly in the small intestine to engage the small intestinal immune axis.

Mechanistic rationale contrasted with probiotics

• Probiotics (as described here) are said to primarily act in the colon, through:
  • Microbial ecosystem interactions
  • Metabolite production
• This product is said to work through the small intestine immune axis, which probiotics are claimed not to engage in the same way.

---

Researchers / sources featured

• Dr. Simbagaill (guest; founder of Songbird Health)
• Mayo Clinic (named institution; referenced as an academic research partner)
• Oxford Longevity Project (named organization)
• Nobel Prize (year unspecified in subtitles) for discovery/understanding of regulatory T cells
• Muir’s textbook of pathology (cited as an educational source used in the 1960s)
• Historical health context mentioned:
  • Industrial accidents
  • Venereal disease
  • Infant mortality
  • Antibiotics-era infectious disease burden (No specific named researchers were given for these.)

No additional individual researchers are explicitly named beyond Dr. Simbagaill.